Leukocyte and White Blood Cell Toxicity during longterm Peptide Receptor Radiotherapy (PRRT) using Y-90 and Lu-177 Labelled Somatostatin Analogues

被引：0
|
作者：
Junak, D. Handkiewicz [1 ]
Baum, R. [2 ]
Jarzab, B. [1 ]
机构：
[1] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Nucl Med, Gliwice, Poland
[2] Zent Klin Bad Berka, Dept Nucl Med, PET Ctr, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2005年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 21 条
  • [1] Toxicity of Peptide Receptor Radiotherapy (PRRT) Using the Somatostatin Analogue DOTA-NOC Labelled with Y-90 or Lu-177
    Junak, D. Handkiewicz
    Baum, R. P.
    Jarzak, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S202 - S202
  • [2] Survival benefits and efficacy of peptide receptor radionuclide therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in pancreatic neuroendocrine tumor (pNET)
    Prasad, V.
    Hoersch, D.
    Hommann, M.
    Zachert, C.
    Baum, R. P.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [3] Pancreatic Neuroendocrine Tumor (pNET): Survival Benefits and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Using Y-90/Lu-177 DOTA-TATE
    Prasad, V
    Hoersch, D.
    Hommann, M.
    Zachert, C.
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 132 - 133
  • [4] Peptide receptor radionuclide therapy (PRRT) of metastatic thyroid cancer using yttrium-90 and lutetium-177 labelled somatostatin analogues: Preliminary results
    Mundschenk, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S240 - S240
  • [5] Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
    Hoersch, D.
    Prasad, V.
    Baum, R. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Renal toxicity analysis in a Peptide Receptor Radionuclide Therapy (PRRT) trial with alternated 177Lu and 90Y-DOTATOC
    Grassi, E.
    Fioroni, F.
    Cremonesi, M.
    Finocchiaro, D.
    Ferrari, M.
    Botta, F.
    Castellani, G.
    Lanconelli, N.
    Filice, A.
    Versari, A.
    Iori, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S399 - S400
  • [7] Lymphocytic toxicity in patients after peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
    Paganelli, G.
    Sierra, M. Lopera
    Agazzi, A.
    Bodei, L.
    Pacifici, M.
    Arico, D.
    Grana, C. M.
    Baio, S. M.
    De Cicco, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S351 - S351
  • [8] Pregnancy and delivery after peptide receptor radionuclide therapy (PRET) using 177Lu/90Y labelled somatostatin analogues without sequelae: outcome in young NEN patients
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [9] Treatment of metastasised neuroendocrine tumours with the radiolabeled somatostatin analogues Lu-177 or Y-90-DOTA-TATE: Long term toxicity and survival in 543 patients
    Baum, R. P.
    Prasad, V.
    Hommann, M.
    Zachert, C.
    Hoersch, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S432 - S433
  • [10] Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
    Sierra, Maribel L.
    Agazzi, Alberto
    Bodei, Lisa
    Pacifici, Monica
    Arico, Demetrio
    De Cicco, Concetta
    Quarna, Jessica
    Sansovini, Maddalena
    De Simone, Michele
    Paganelli, Giovanni
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (06) : 659 - 665
123